Stockscreener 앱 받기
71.70
0.38%
-0.27
시간 외 거래:
71.70
전일 마감가:
$71.97
열려 있는:
$71.58
하루 거래량:
564.33K
Relative Volume:
0.33
시가총액:
$5.98B
수익:
$1.73B
순이익/손실:
$682.64M
주가수익비율:
9.2679
EPS:
7.7364
순현금흐름:
$411.18M
1주 성능:
-2.20%
1개월 성능:
-8.15%
6개월 성능:
+3.24%
1년 성능:
+47.23%
1일 변동 폭
$70.85
$72.13
1주일 범위
$70.85
$75.00
52주 변동 폭
$47.94
$90.87
PTC 테라퓨틱스 Stock (PTCT) Company Profile
명칭
Ptc Therapeutics Inc
전화
(908) 222-7000
주소
500 WARREN CORPORATE CENTER DRIVE, WARREN, NJ
Compare PTCT vs VRTX, REGN, ARGX, RVMD, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PTCT
Ptc Therapeutics Inc
|
71.70 | 6.06B | 1.73B | 682.64M | 411.18M | 7.7364 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
PTC 테라퓨틱스 Stock (PTCT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-10 | 개시 | Raymond James | Outperform |
| 2026-01-28 | 재개 | Barclays | Overweight |
| 2025-12-01 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-10-20 | 개시 | Wells Fargo | Overweight |
| 2025-06-17 | 개시 | Truist | Buy |
| 2025-05-09 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2025-05-07 | 업그레이드 | Citigroup | Sell → Neutral |
| 2025-03-11 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2025-03-07 | 개시 | Scotiabank | Sector Perform |
| 2024-12-13 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-03 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-10-10 | 재개 | Raymond James | Mkt Perform |
| 2024-09-04 | 개시 | Robert W. Baird | Outperform |
| 2024-08-26 | 재개 | UBS | Buy |
| 2024-05-20 | 업그레이드 | Raymond James | Underperform → Mkt Perform |
| 2023-12-19 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2023-12-08 | 개시 | Wells Fargo | Overweight |
| 2023-10-30 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2023-10-27 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2023-10-06 | 다운그레이드 | Truist | Buy → Hold |
| 2023-09-18 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2023-09-15 | 다운그레이드 | Raymond James | Outperform → Underperform |
| 2023-03-17 | 개시 | SVB Securities | Market Perform |
| 2022-12-14 | 개시 | Goldman | Sell |
| 2022-09-12 | 개시 | Jefferies | Buy |
| 2022-09-09 | 개시 | Morgan Stanley | Equal-Weight |
| 2022-09-01 | 개시 | Citigroup | Buy |
| 2022-04-04 | 재개 | Cantor Fitzgerald | Overweight |
| 2021-10-18 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2021-04-26 | 재개 | Credit Suisse | Neutral |
| 2021-03-29 | 업그레이드 | RBC Capital Mkts | Underperform → Sector Perform |
| 2021-02-12 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2021-01-05 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-11-30 | 다운그레이드 | RBC Capital Mkts | Sector Perform → Underperform |
| 2020-10-30 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-10-28 | 개시 | UBS | Neutral |
| 2020-10-07 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2020-08-25 | 개시 | Raymond James | Outperform |
| 2020-04-09 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-02-20 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-02-20 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-11-12 | 개시 | SunTrust | Buy |
| 2019-05-13 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2019-04-11 | 개시 | Bernstein | Outperform |
| 2018-10-03 | 업그레이드 | BofA/Merrill | Underperform → Neutral |
| 2018-10-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-07-19 | 개시 | Credit Suisse | Outperform |
| 2018-06-18 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-04-04 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2018-01-29 | 재개 | RBC Capital Mkts | Sector Perform |
| 2017-11-16 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2017-10-26 | 다운그레이드 | BofA/Merrill | Neutral → Underperform |
| 2017-10-09 | 다운그레이드 | JP Morgan | Neutral → Underweight |
모두보기
PTC 테라퓨틱스 주식(PTCT)의 최신 뉴스
Price to earnings forward of PTC Therapeutics, Inc. – BX:P91 - TradingView
PTC Therapeutics Targets Fabry Gene Therapy in $111M Bankruptcy Auction Deal - marketbeat.com
The week in pharma: action, reaction and insight – week to August 14, 2026 - The Pharma Letter
Assenagon Asset Management S.A. Has $563,000 Holdings in PTC Therapeutics, Inc. $PTCT - marketbeat.com
PTC Therapeutics Is Maintained at Overweight by Barclays - moomoo.com
Walleye Capital LLC Takes $1.59 Million Position in PTC Therapeutics, Inc. $PTCT - marketbeat.com
PTC Therapeutics Expands Rare Disease Portfolio with 'Unique Opportunity' - Sahm
PTCT Maintained by Barclays -- Price Target Raised to $122 - GuruFocus
PTC Therapeutics’ $211M Bid Wins Bankruptcy Auction for Sangamo Gene Therapy - MedCity News
Cantor Fitzgerald Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Maintains Target Price $130 - moomoo.com
PTC takes a chance on Sangamo’s Fabry disease gene therapy - BioPharma Dive
PTCT Maintains Overweight Rating by Wells Fargo -- Price Target Raised to $109 - GuruFocus
PTC to Acquire Sangamo’s Fabry Disease Gene Therapy - contractpharma.com
PTC Therapeutics to Acquire ST-920 Fabry Gene Therapy - TipRanks
Bankrupt Sangamo offloads assets to Lilly, PTC in $161M sale - BioSpace
Form 8K PTC Therapeutics Inc For: 13 August By Investing.com - Investing.com Nigeria
PTC to expand rare disease portfolio with ST-920 buy - The Pharma Letter
PTC Therapeutics, Lilly to buy up bits of Sangamo in bankruptcy auction - Endpoints News
PTC Therapeutics, Inc. (PTCT) Stock Forecasts - Yahoo Finance
Bankrupt Sangamo scores at least $163 million in asset sale, which had two big winners - The Business Journals
PTC Therapeutics to acquire Fabry disease gene therapy ST-920 - Investing.com
PTC Therapeutics to acquire Fabry disease gene therapy ST-920 By Investing.com - Investing.com India
PTC to Expand Rare Disease Portfolio with Acquisition of BLA-Stage ST-920 Fabry Disease Program - PR Newswire
How Ptc Therapeutics Inc. (PTCT) Affects Rotational Strategy Timing - Stock Traders Daily
Why PTC Therapeutics (PTCT) Is Up 6.7% After Profit Beat, Higher Guidance And New Board Appointment - simplywall.st
Is PTC Therapeutics (PTCT) Undervalued As Profit And Revenue Guidance Jumped? - Sahm
Don't Ignore The Insider Selling In PTC Therapeutics - moomoo.com
Have PTC Therapeutics Insiders Been Selling Stock? - simplywall.st
Zacks Research Downgrades PTC Therapeutics (NASDAQ:PTCT) to Hold - MarketBeat
PTC Therapeutics Inc (PTCT) Stock News Today - TradingKey
PTC Therapeutics CEO Klein sells $705,722 in company stock By Investing.com - Investing.com South Africa
PTC Therapeutics Inc (PTCT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
PTC Therapeutics CEO Klein sells $705,722 in company stock - Investing.com
Bank of America Corp DE Raises Position in PTC Therapeutics, Inc. $PTCT - marketbeat.com
PTC Therapeutics, Inc. $PTCT Stock Position Lifted by California State Teachers Retirement System - MarketBeat
Insider Selling: PTC Therapeutics (NASDAQ:PTCT) CEO Sells 10,292 Shares of Stock - MarketBeat
PTC Therapeutics (PTCT) CEO sells 10,292 shares to cover taxes - Stock Titan
PTC Therapeutics (PTCT) Stock Fair Value Edges Higher After Analyst Target Increases - finance.yahoo.com
PTCT Therapeutics (PTCT) insider to sell 10,292 vested shares under Rule 144 - Stock Titan
PTC Therapeutics (PTCT) Loses 20.3% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - finance.yahoo.com
PTC Therapeutics, Inc. (PTCT) Stock Analysis: A 43.66% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Barclays Keeps Their Buy Rating on PTC Therapeutics (PTCT) - The Globe and Mail
Defilade Capital Management L.P. Invests $25.63 Million in PTC Therapeutics, Inc. $PTCT - marketbeat.com
Empowered Funds LLC Sells 192,506 Shares of PTC Therapeutics, Inc. $PTCT - MarketBeat
Sei Investments Co. Raises Stake in PTC Therapeutics, Inc. $PTCT - marketbeat.com
PTC Therapeutics (NASDAQ:PTCT) Upgraded to "Strong-Buy" at Wall Street Zen - MarketBeat
First Trust Advisors LP Decreases Stock Holdings in PTC Therapeutics, Inc. $PTCT - MarketBeat
PTC Therapeutics, Inc. Stock 12‑Month Price Target Raised to $97.86, Implies 30% Upside - TradingView
PTC Therapeutics Falls Despite Strong Q2 Results as Investors Weigh One-Time Boosts and Legacy Product Pressure - Quiver Quantitative
PTC Therapeutics, Inc. Stock 12‑Month Price Target Raised to $96.93, Implies 28% Upside - TradingView
PTC Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
PTC 테라퓨틱스 (PTCT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.52%
0.07%
자본화:
|
볼륨(24시간):